(131)~I-Anti-c-erb2免疫导向治疗卵巢癌的实验研究

The Experimental Study of Radioimmunotherapy on Ovarian Carcinoma Using 131I Anti c erb2 McAB

【目的】观察放射性核素标记针对癌蛋白为靶点的单克隆抗体载体外对卵巢癌细胞的抑制作用。【方法】应用氯胺T法将131I和抗c-erb2单克隆抗体标记,取不同浓度的131I-Anti-c-erb2与SKOV3细胞共同培养,MTT法检测其对SKOV3细胞生长的抑制作用。【结果】体外单抗浓度为22.20mg/L时,131I-Anti-c-erb2的相对抑制率为64.85%,可以明显抑制SKOV3细胞,未标记的抗c-erb2单抗的相对抑制率为3.40%,对SKOV3细胞的生长几乎没有抑制作用。【结论】131I-Anti-c-erb2能够有效抑制肿瘤细胞的生长,适合应用于卵巢癌的免疫导向治疗。

To observe the effect of anti oncoprotein monoclonal antibody labeled with radio isotope 131I on ovarian carcinoma cells. Anti c erb2 monoclonal antibody was labeled with 131I using Chloramine T. SKOV3 cells were cultured with 131I Anti c erb2. The inhibition was detected with MTT. When the monoclonal antibody concentration was 22.20 mg/L, the relative inhibition rate of 131I Anti c erb2 was 64.85%. It could inhibit the growth of SKOV3 cells, on the contrary, the relative inhibition rate of anti c erb2 without 131I was 3.40%, it could hardly inhibit the growth of SKOV3 cells in vitro. [Conclusion]131I Anti c erb2 can effectively inhibit the growth of tumor cells and might be suitable to be used in immune target therapy.